CL4H6 is a lipid for RNA and vaccine delivery

Related CAS #: 2256087-35-9    

Synonym: CL4H6; CL-4H6; CL 4H6;

IUPAC/Chemical Name: 7-(4-(dipropylamino)butyl)-7-hydroxytridecane-1,13-diyl dioleate

InChi Key: ZFFZMGJMZGAGMF-SXAUZNKPSA-N

InChi Code: InChI=1S/C59H113NO5/c1-5-9-11-13-15-17-19-21-23-25-27-29-31-33-39-47-57(61)64-55-45-37-35-41-49-59(63,51-43-44-54-60(52-7-3)53-8-4)50-42-36-38-46-56-65-58(62)48-40-34-32-30-28-26-24-22-20-18-16-14-12-10-6-2/h21-24,63H,5-20,25-56H2,1-4H3/b23-21-,24-22-

SMILES Code: CCCN(CCC)CCCCC(CCCCCCOC(CCCCCCC/C=C\CCCCCCCC)=O)(O)CCCCCCOC(CCCCCCC/C=C\CCCCCCCC)=O

Appearance: liquid

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

References:

1: Sanghani A, Kafetzis KN, Sato Y, Elboraie S, Fajardo-Sanchez J, Harashima H, Tagalakis AD, Yu-Wai-Man C. Novel PEGylated Lipid Nanoparticles Have a High Encapsulation Efficiency and Effectively Deliver MRTF-B siRNA in Conjunctival Fibroblasts. Pharmaceutics. 2021 Mar 13;13(3):382. doi: 10.3390/pharmaceutics13030382. PMID: 33805660; PMCID: PMC7998417.

2: Sato Y, Nakamura T, Yamada Y, Harashima H. The nanomedicine rush: New strategies for unmet medical needs based on innovative nano DDS. J Control Release. 2021 Feb 10;330:305-316. doi: 10.1016/j.jconrel.2020.12.032. Epub 2020 Dec 20. PMID: 33358975.

3: Shobaki N, Sato Y, Suzuki Y, Okabe N, Harashima H. Manipulating the function of tumor-associated macrophages by siRNA-loaded lipid nanoparticles for cancer immunotherapy. J Control Release. 2020 Sep 10;325:235-248. doi: 10.1016/j.jconrel.2020.07.001. Epub 2020 Jul 8. PMID: 32649972.

4: Nakamura T, Yamada Y, Sato Y, Khalil IA, Harashima H. Innovative nanotechnologies for enhancing nucleic acids/gene therapy: Controlling intracellular trafficking to targeted biodistribution. Biomaterials. 2019 Oct;218:119329. doi: 10.1016/j.biomaterials.2019.119329. Epub 2019 Jul 4. PMID: 31306827.

5: Sato Y, Hashiba K, Sasaki K, Maeki M, Tokeshi M, Harashima H. Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo. J Control Release. 2019 Feb 10;295:140-152. doi: 10.1016/j.jconrel.2019.01.001. Epub 2019 Jan 2. PMID: 30610950.